{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: France Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/fr/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/fr/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from France, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:bb643f1225912a251281d0e87f94542ea3b32a3d4977d536396cbe0b42f96c8c", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-150802661.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-150802661.html", "title": "European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading", "content_text": "European equities traded in the US as American depositary receipts were tracking lower late Friday morning, declining 0.35% to 1,962.14 on the S&P Europe Select ADR Index, which is up 0.17% for the week so far.From continental Europe, the gainers were led by semiconductor company Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-14T15:08:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "ALCLS"], "_sharemaestro": {"country": "France", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALCLS", "name": "Cellectis S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/094ba8d4-1a5b-4ff5-a789-630e49274513/"}]}}, {"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:099661ecc0bba4c15ccaa35c84a4fa3d5949068502d3e0f1d3319564d315019c", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-rise-151440591.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-rise-151440591.html", "title": "European Equities Traded in the US Rise in Thursday Trading", "content_text": "European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-13T15:14:40+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "ALCLS"], "_sharemaestro": {"country": "France", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALCLS", "name": "Cellectis S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/094ba8d4-1a5b-4ff5-a789-630e49274513/"}]}}, {"id": "source:7fbcd1fd43abb4f847bc1485b0c3a2b85289eafaacf3930507fe4934a03f5b05", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPZmdZak5XTWs4eS1OLWpXc3luZWROU2I0UzEweEgxM3d2aFlYZjR5ZHUxdGtRbTh0SlU5ZjI5bUdxeWNHRzZ1LTk4YTVHX0Z5dm9FSWREWlp5dUxsLVJJbW1ScTFTb3JYZERvOW9DRFowOVVheVZOWGhoUVc5VGFEWDJpSE9rZDE2dklzRElULTROMFp5Mjd5dnRSTnFiTTR1TVh3b09FOGEtaHgxSzlBQUNR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPZmdZak5XTWs4eS1OLWpXc3luZWROU2I0UzEweEgxM3d2aFlYZjR5ZHUxdGtRbTh0SlU5ZjI5bUdxeWNHRzZ1LTk4YTVHX0Z5dm9FSWREWlp5dUxsLVJJbW1ScTFTb3JYZERvOW9DRFowOVVheVZOWGhoUVc5VGFEWDJpSE9rZDE2dklzRElULTROMFp5Mjd5dnRSTnFiTTR1TVh3b09FOGEtaHgxSzlBQUNR?oc=5", "title": "Valneva d\u00e9voile des r\u00e9sultats en baisse comme pr\u00e9vu", "content_text": "Valneva d\u00e9voile des r\u00e9sultats en baisse comme pr\u00e9vu", "date_published": "2026-08-13T09:01:23+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:2b01ca1fb4082ad003946edd1a168f34758796aeccf23f8dae47ea177ab294c9", "url": "https://seekingalpha.com/news/4632084-valneva-gaap-eps-of-035-revenue-of-6584m-reaffirms-fy-2026?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632084-valneva-gaap-eps-of-035-revenue-of-6584m-reaffirms-fy-2026?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Valneva GAAP EPS of -\u20ac0.35, revenue of \u20ac65.84M; reaffirms FY 2026", "content_text": "* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -\u20ac0.35. * Revenue of \u20ac65.84M (-32.5% Y/Y). * Solid cash position of \u20ac121.5 million as of end June 2026. * FINANCIAL OUTLOOK * Despite the continued adverse impact of the geopolitical environment on travel, Valneva reaffirmed its 2026 guidance with expected product sales of \u20ac135 million to \u20ac150 million and total revenues of \u20ac145 million to \u20ac160 million. * Product gross margins are expected to ", "date_published": "2026-08-13T06:05:24+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:cd43458cb731296f7072733bebb601944bde7b3165366430c94af54a3ae6c0ff", "url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "external_url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "title": "Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates", "content_text": "VALNEVA SE Total product sales of \u20ac64.0 million In-line with expectations; full-year guidance of \u20ac135 -150 million reaffirmed Solid cash position of \u20ac121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic about obtaining registration for the vaccine candidate3 Lyon (France), August 13, 2026 \u2013", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:9f842a2e9d0e3815139711afb5a91d6d769267feaa2e8868172623d73588c0d7", "url": "https://www.nasdaq.com/articles/innate-pharma-jumps-after-sobi-deal-advance-lacutamab-phase-3-appoints-markus-jensen-cmo", "external_url": "https://www.nasdaq.com/articles/innate-pharma-jumps-after-sobi-deal-advance-lacutamab-phase-3-appoints-markus-jensen-cmo", "title": "Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO", "content_text": "(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of Lacutamab, an investigational anti-KIR3DL2 antibody in cutaneous T-cell lymphoma (CTCL). Under the agreement terms, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome, and Sobi will receive exclusive global rights to commercialise lacuta", "date_published": "2026-08-10T10:21:29+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "IPH"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IPH", "name": "Innate Pharma S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6c317cc7-90f7-4370-b7d0-abc75a3227ae/"}]}}, {"id": "source:bc802f08c8ff72acb62f2e3bf4cf121b800baa1082d3bc2b406866456d78d728", "url": "https://www.nasdaq.com/articles/sobi-innate-join-conduct-tellomak-3-phase-3-confirmatory-trial-cutaneous-t-cell-lymphoma", "external_url": "https://www.nasdaq.com/articles/sobi-innate-join-conduct-tellomak-3-phase-3-confirmatory-trial-cutaneous-t-cell-lymphoma", "title": "Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma", "content_text": "(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of cutaneous T cell lymphoma. Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. Sobi will pay Innate Pharma $75 million, payable on closing. Innate will be eligible to receive", "date_published": "2026-08-10T07:10:24+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "IPH"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IPH", "name": "Innate Pharma S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6c317cc7-90f7-4370-b7d0-abc75a3227ae/"}]}}, {"id": "source:1ccb6d99c5cf0b92518425bf43eb9ae2dd5e9d8799ba160e8c558c14d02bf601", "url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "title": "Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma", "content_text": "STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) (\"Innate\" or the \"Company\") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing ", "date_published": "2026-08-10T06:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "IPH"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IPH", "name": "Innate Pharma S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6c317cc7-90f7-4370-b7d0-abc75a3227ae/"}]}}, {"id": "source:f8f2abca4245617aebc94d1305860be1d0ca4c3307b2ff251643abf7571e1402", "url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE02cTlkd3ZuYmFiMlVpYnZoZGxUTkstU1BJY1o5bEVDT3NxXzBlZjZWRVlPOUNHLU1rTVdvLVIxVXY5UGpNZjFkbjRlaHJpdFBfOXdOaHdxWVk4djV4M0ZWTw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE02cTlkd3ZuYmFiMlVpYnZoZGxUTkstU1BJY1o5bEVDT3NxXzBlZjZWRVlPOUNHLU1rTVdvLVIxVXY5UGpNZjFkbjRlaHJpdFBfOXdOaHdxWVk4djV4M0ZWTw?oc=5", "title": "\u00c9valuations, estimations et pr\u00e9visions d\u2019analystes pour OSE Immunotherapeutics SA (6OP.HM)", "content_text": "\u00c9valuations, estimations et pr\u00e9visions d\u2019analystes pour OSE Immunotherapeutics SA (6OP.HM)", "date_published": "2026-08-07T10:30:34+00:00", "authors": [{"name": "Market source"}], "tags": ["Market update", "OSE"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OSE", "name": "OSE Immunotherapeutics SA", "sentiment_url": "https://sharemaestro.com/sentiment/04bcbcf5-f8aa-4784-84d7-6354d56388b7/"}]}}, {"id": "source:8cbdeba03ccf7367784e16538e35587715235b038ef4da266bc15fe5e66bdb33", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQYVBlak4xbXdpNkVXRWxxcTRETkI3ZEhyajh6MExIUEZIM29jMDNqUzhUcEdwbnhqN251U1J1dnpXVkRrWi0tQ3hpa1lPYS1qdkNGajlaZml1M2pFQm9tT29JXzU5dHEwMmpZbC1RajQyVXBoa2c1VGRDdlpIMmxBZUEwVS1jNmhqMmZLSnh2eDA1LTYwdTJabWJkWlNVek1zSklQZFpzajJEQU9lamViYkNQNEotelhXUV8xVE54UnlVSkwxNFNnYWVEZlZjRnFzcGRTQmVHdjF3RVBOZHN3RQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQYVBlak4xbXdpNkVXRWxxcTRETkI3ZEhyajh6MExIUEZIM29jMDNqUzhUcEdwbnhqN251U1J1dnpXVkRrWi0tQ3hpa1lPYS1qdkNGajlaZml1M2pFQm9tT29JXzU5dHEwMmpZbC1RajQyVXBoa2c1VGRDdlpIMmxBZUEwVS1jNmhqMmZLSnh2eDA1LTYwdTJabWJkWlNVek1zSklQZFpzajJEQU9lamViYkNQNEotelhXUV8xVE54UnlVSkwxNFNnYWVEZlZjRnFzcGRTQmVHdjF3RVBOZHN3RQ?oc=5", "title": "Inventiva annonce ses r\u00e9sultats financiers pr\u00e9liminaires pour le premier semestre 2026\u00b9", "content_text": "Inventiva annonce ses r\u00e9sultats financiers pr\u00e9liminaires pour le premier semestre 2026\u00b9", "date_published": "2026-07-29T20:00:07+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "IVA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IVA", "name": "Inventiva S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/5468d44e-7106-4c2a-bb53-f659e64725be/"}]}}, {"id": "source:57df145b4bdb0096611a275ae90177e01accfb8859dedbb76d712e1cd4325537", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBZMVF0ZDVsVjhUSlQ3a1VTaF9HVDZDRV9CLTc0bHlTNHNOU19ra2JfN3JTUE1wS2gwVzNXMVlyTzZ0VUtKM2pfc2w5MzFfWTRLMUJhekRDcjRTQ0E0WWtEXzBvWjhPc1U?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBZMVF0ZDVsVjhUSlQ3a1VTaF9HVDZDRV9CLTc0bHlTNHNOU19ra2JfN3JTUE1wS2gwVzNXMVlyTzZ0VUtKM2pfc2w5MzFfWTRLMUJhekRDcjRTQ0E0WWtEXzBvWjhPc1U?oc=5", "title": "ADOCIA publie ses r\u00e9sultats financiers du deuxi\u00e8me trimestre 2026 et fait le point sur ses activit\u00e9s", "content_text": "ADOCIA publie ses r\u00e9sultats financiers du deuxi\u00e8me trimestre 2026 et fait le point sur ses activit\u00e9s", "date_published": "2026-07-23T07:00:00+00:00", "authors": [{"name": "Business Wire"}], "tags": ["Market update", "ADOC"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ADOC", "name": "Adocia SA", "sentiment_url": "https://sharemaestro.com/sentiment/f0ecae67-1c8c-4894-85ae-8412f647366c/"}]}}, {"id": "source:8e6649c23ffde1086c2dcd43b223097d25c0f5575848c8eecbd712a399950aaa", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE1uLUZYdTB5MVNrWUxkd3Z2U2xPVFotU3ZNZDlycmdWS21hUWFkT2taQnRJb0stSGlWcmRhLTJ4MnZwNjNNbHhEMU4ta3RRRHpwX05QYUpSZW5aX2Vndk9CbC13Qi1mQW1VZnBVRU13cmQxdzhBeEE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE1uLUZYdTB5MVNrWUxkd3Z2U2xPVFotU3ZNZDlycmdWS21hUWFkT2taQnRJb0stSGlWcmRhLTJ4MnZwNjNNbHhEMU4ta3RRRHpwX05QYUpSZW5aX2Vndk9CbC13Qi1mQW1VZnBVRU13cmQxdzhBeEE?oc=5", "title": "Valneva SE: Objectif de Cours et Consensus des Analystes | VLA | FR0004056851", "content_text": "Valneva SE: Objectif de Cours et Consensus des Analystes | VLA | FR0004056851", "date_published": "2026-06-30T07:00:00+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:727e5e44de211f72927cbecd5fec88007266281fac58f6b4e840effa5270965d", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9HTTNnNkYzNW5HdzRicllFWnJMWnVvSWVZTXhwV0xBM3ZNMWh3X3J1NllXX1BqVjhlM29ITXV2TUtXZ2hnSGI5dEpqdjhicTd1M2ZZYmlheVVSYXJUb0hxeEJDN19PV0J2Rm9VUWtUcWo4NUd4c1BaTkxPX3Q?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9HTTNnNkYzNW5HdzRicllFWnJMWnVvSWVZTXhwV0xBM3ZNMWh3X3J1NllXX1BqVjhlM29ITXV2TUtXZ2hnSGI5dEpqdjhicTd1M2ZZYmlheVVSYXJUb0hxeEJDN19PV0J2Rm9VUWtUcWo4NUd4c1BaTkxPX3Q?oc=5", "title": "ALCLS Pr\u00e9visions - Objectif de prix pour 2027", "content_text": "ALCLS Pr\u00e9visions - Objectif de prix pour 2027", "date_published": "2026-06-26T23:29:10+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "ALCLS"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALCLS", "name": "Cellectis S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/094ba8d4-1a5b-4ff5-a789-630e49274513/"}]}}, {"id": "source:8e4c5980334391a4928cbb3008632992faabfd1c09714a43bf438bfbc2f793a2", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE12SWZMSVZzUTlaa1d1MjBHaGpRVTJyb1Y3WGVjZXZQQWxXbU92RlZ1UWRnbXJGNlRkTTlvQkVJYW9EbkFEQkNxMHNobGFmWVltZkFpMkRadmYyOEloWjVKcHl2eVZ2eEdTZHlzZ2stQTBOTjdkNFJTaTdYalA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE12SWZMSVZzUTlaa1d1MjBHaGpRVTJyb1Y3WGVjZXZQQWxXbU92RlZ1UWRnbXJGNlRkTTlvQkVJYW9EbkFEQkNxMHNobGFmWVltZkFpMkRadmYyOEloWjVKcHl2eVZ2eEdTZHlzZ2stQTBOTjdkNFJTaTdYalA?oc=5", "title": "MEDCL Pr\u00e9visions - Objectif de prix pour 2027", "content_text": "MEDCL Pr\u00e9visions - Objectif de prix pour 2027", "date_published": "2026-06-26T23:25:21+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "MEDCL"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MEDCL", "name": "MedinCell S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c1a6a004-ed02-43d9-a6ea-21f7d30551c3/"}]}}, {"id": "source:3cfc9f7302f325f3ac5b27df024094bce3b89eb1581b1b4d1fc9984e1b71572c", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFBXQUJ3RVVzZWZDdEZlLU11WlU2VHJEdTEtUmdzY0pBeDE5dTZhNFlkalZ3MXpUOTVuWTlqV3FBR0pyQ0VfdXZobElRODFZT1lKU09Rdk5ydm1iaEMtT20tM2lzbDZ1TGZFcmM1MnBOU0Z6NGQxeFAxRHdCUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFBXQUJ3RVVzZWZDdEZlLU11WlU2VHJEdTEtUmdzY0pBeDE5dTZhNFlkalZ3MXpUOTVuWTlqV3FBR0pyQ0VfdXZobElRODFZT1lKU09Rdk5ydm1iaEMtT20tM2lzbDZ1TGZFcmM1MnBOU0Z6NGQxeFAxRHdCUQ?oc=5", "title": "ABVX Pr\u00e9visions - Objectif de prix pour 2027", "content_text": "ABVX Pr\u00e9visions - Objectif de prix pour 2027", "date_published": "2026-06-25T11:57:52+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "ABVX"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABVX", "name": "ABIVAX Soci\u00e9t\u00e9 Anonyme", "sentiment_url": "https://sharemaestro.com/sentiment/31eb5de8-5e84-4e38-ba2e-0b160353627c/"}]}}, {"id": "source:b8c0dbb7dee782158233055ca0d834042267a52211d88316d3c52797acc9baf8", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE55QWdmd1psLVZCTW9DNUZRZTBxbjVPRG5WWW04LVM4UmpqOFV5bW1DdXNtUUZRVldmNjFHcm5BMFJXeHF4UUI3eDRndnlRYjhzSzAtQlpjdVlpdWNNWXFCTFg3WjEwZHM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE55QWdmd1psLVZCTW9DNUZRZTBxbjVPRG5WWW04LVM4UmpqOFV5bW1DdXNtUUZRVldmNjFHcm5BMFJXeHF4UUI3eDRndnlRYjhzSzAtQlpjdVlpdWNNWXFCTFg3WjEwZHM?oc=5", "title": "Aelis Farma : Mise \u00e0 disposition du descriptif du programme de rachat d\u2019actions", "content_text": "Aelis Farma : Mise \u00e0 disposition du descriptif du programme de rachat d\u2019actions", "date_published": "2026-06-22T07:00:00+00:00", "authors": [{"name": "Business Wire"}], "tags": ["Market update", "AELIS"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AELIS", "name": "Aelis Farma SA", "sentiment_url": "https://sharemaestro.com/sentiment/f76a96b8-fae1-4e23-a5bf-bc0d22f21b87/"}]}}, {"id": "source:b084dbdf731a9af7cee0ed96e3411660edb4ffdda765a69866f0ebafb2c51a59", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPLWZmUlpiY2pwUHpoVGlHSmgtQ0JoaVk3T2hrMUZUTzBHR2ltVXVyMzNxWFBMNF9RMDh6aTRweUU2YktXLVZUY2ZJSklkR0FvQU1EekJmenRxTTU1dHFybk5IbnlfZFBrRUwzb05Qb01BS29WZ040cjRCeDJVSHVqWkxIaWNGaUJTNlRXTG5kX1dhOVU5OGlJNy1EYmxtZlc0dFVTWmFxU2htQlF1TnN3VnA3UkU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPLWZmUlpiY2pwUHpoVGlHSmgtQ0JoaVk3T2hrMUZUTzBHR2ltVXVyMzNxWFBMNF9RMDh6aTRweUU2YktXLVZUY2ZJSklkR0FvQU1EekJmenRxTTU1dHFybk5IbnlfZFBrRUwzb05Qb01BS29WZ040cjRCeDJVSHVqWkxIaWNGaUJTNlRXTG5kX1dhOVU5OGlJNy1EYmxtZlc0dFVTWmFxU2htQlF1TnN3VnA3UkU?oc=5", "title": "Medincell en forte baisse apr\u00e8s les r\u00e9sultats annuels", "content_text": "Medincell en forte baisse apr\u00e8s les r\u00e9sultats annuels", "date_published": "2026-06-17T07:00:00+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "MEDCL"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MEDCL", "name": "MedinCell S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c1a6a004-ed02-43d9-a6ea-21f7d30551c3/"}]}}, {"id": "source:83219bb0cd68aeb80204b4b142d7a0089f3f5c3d73028a25db6396885f6690af", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE4zTHJXMl9Md2cyVDRSMExVZHNvYmdtN3p4VEF6ZDFoZDJzWC01Q1ZHdlAzVV9jaGRTc2pzbW5rbU1xTzBRZXFLSVBPakVHa0pnOFFyejFKcmw3OGo0YnNDaWd3WXQzcGM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE4zTHJXMl9Md2cyVDRSMExVZHNvYmdtN3p4VEF6ZDFoZDJzWC01Q1ZHdlAzVV9jaGRTc2pzbW5rbU1xTzBRZXFLSVBPakVHa0pnOFFyejFKcmw3OGo0YnNDaWd3WXQzcGM?oc=5", "title": "ADOCIA annonce la pr\u00e9sentation des donn\u00e9es de phase 3 de THDB0206 (BioChaperone\u00ae Lispro) dans le diab\u00e8te de type 2 lors des 86e sessions scientifiques de l'ADA, confirmant les r\u00e9sultats positifs d\u00e9j\u00e0 annonc\u00e9s en juillet 2025", "content_text": "ADOCIA annonce la pr\u00e9sentation des donn\u00e9es de phase 3 de THDB0206 (BioChaperone\u00ae Lispro) dans le diab\u00e8te de type 2 lors des 86e sessions scientifiques de l'ADA, confirmant les r\u00e9sultats positifs d\u00e9j\u00e0 annonc\u00e9s en juillet 2025", "date_published": "2026-06-08T07:00:00+00:00", "authors": [{"name": "Business Wire"}], "tags": ["Market update", "ADOC"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ADOC", "name": "Adocia SA", "sentiment_url": "https://sharemaestro.com/sentiment/f0ecae67-1c8c-4894-85ae-8412f647366c/"}]}}, {"id": "source:90cad6becbbc95802779733e788bc7cbf41c447fa0db58056fef514f3eb60c49", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPVmZ2M0dkakpyZ2ZCZm93U3RHODNlemdpYkdJRzFVclljSkR1VUFXa0UtSW1ISmhIV092c1FUMDNnaUJPNXU2OEdCTlptejBQUFk4dXRXVVFjMWtrTWtXS2h0REZleDNKTTl5enVoc0NQa0h6bVhuNEtkaHNTRTd3bEhEY282cUJfRWVLVDR2NA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPVmZ2M0dkakpyZ2ZCZm93U3RHODNlemdpYkdJRzFVclljSkR1VUFXa0UtSW1ISmhIV092c1FUMDNnaUJPNXU2OEdCTlptejBQUFk4dXRXVVFjMWtrTWtXS2h0REZleDNKTTl5enVoc0NQa0h6bVhuNEtkaHNTRTd3bEhEY282cUJfRWVLVDR2NA?oc=5", "title": "Valneva chute puis remonte apr\u00e8s ses r\u00e9sultats T1", "content_text": "Valneva chute puis remonte apr\u00e8s ses r\u00e9sultats T1", "date_published": "2026-05-13T07:00:00+00:00", "authors": [{"name": "XTB.com"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:3b98af782e83100bbad1ef862558d6176703eb46587c709c507552baeb0478c7", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTFAtZzNPUU42V2Z4TjZUbjBLR3pqT191Ulg2cUxORmdTT0VGVWd1ZFNSWUhaUWJUdjdCUHVVcVNBLW9qZXNGanBxMjdSLUxkUTlxdXIyWjZiWVN4MXJRMXVzcm9xV2VmYXc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTFAtZzNPUU42V2Z4TjZUbjBLR3pqT191Ulg2cUxORmdTT0VGVWd1ZFNSWUhaUWJUdjdCUHVVcVNBLW9qZXNGanBxMjdSLUxkUTlxdXIyWjZiWVN4MXJRMXVzcm9xV2VmYXc?oc=5", "title": "ADOCIA publie ses r\u00e9sultats financiers du premier trimestre 2026 et fait le point sur ses activit\u00e9s", "content_text": "ADOCIA publie ses r\u00e9sultats financiers du premier trimestre 2026 et fait le point sur ses activit\u00e9s", "date_published": "2026-05-12T07:00:00+00:00", "authors": [{"name": "Business Wire"}], "tags": ["Market update", "ADOC"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ADOC", "name": "Adocia SA", "sentiment_url": "https://sharemaestro.com/sentiment/f0ecae67-1c8c-4894-85ae-8412f647366c/"}]}}, {"id": "source:ca2f803a7ab4ffa7c112d0f00d5dc66378d0919698d77c4b5dddef8b2b432b64", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "OSE Immunotherapeutics publie ses r\u00e9sultats financiers consolid\u00e9s non audit\u00e9s pour l\u2019exercice 2025 et sa situa", "content_text": "OSE Immunotherapeutics publie ses r\u00e9sultats financiers consolid\u00e9s non audit\u00e9s pour l\u2019exercice 2025 et sa situa", "date_published": "2026-04-30T07:00:00+00:00", "authors": [{"name": "Boursorama"}], "tags": ["Market update", "OSE"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OSE", "name": "OSE Immunotherapeutics SA", "sentiment_url": "https://sharemaestro.com/sentiment/04bcbcf5-f8aa-4784-84d7-6354d56388b7/"}]}}, {"id": "source:92e4cce566e9b86c87540a6b60446df733b99732982c6a07c19d5a36be4ccf1e", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9vSVpaTVJTcHJTaW1tNUhJYU95ZmFTbDlOejBQOEdtUjJfWDExeDdWY1c2Z2hJdkdJVzg1NGZfZ1FSOTBfazlzTk9pbVhtdERSWERCamQ2aHQ3RFFWVlRjeHNPaGxwTGs?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9vSVpaTVJTcHJTaW1tNUhJYU95ZmFTbDlOejBQOEdtUjJfWDExeDdWY1c2Z2hJdkdJVzg1NGZfZ1FSOTBfazlzTk9pbVhtdERSWERCamQ2aHQ3RFFWVlRjeHNPaGxwTGs?oc=5", "title": "ADOCIA annonce ses r\u00e9sultats annuels 2025 et fait le point sur ses activit\u00e9s et sa situation financi\u00e8re", "content_text": "ADOCIA annonce ses r\u00e9sultats annuels 2025 et fait le point sur ses activit\u00e9s et sa situation financi\u00e8re", "date_published": "2026-04-21T07:00:00+00:00", "authors": [{"name": "Business Wire"}], "tags": ["Market update", "ADOC"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ADOC", "name": "Adocia SA", "sentiment_url": "https://sharemaestro.com/sentiment/f0ecae67-1c8c-4894-85ae-8412f647366c/"}]}}, {"id": "source:9c2ac6ff03cc18301752f2a582d3805e6af706a3f6df8aef660e279662db70bb", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMkJaOG1LR0kwNzlyTkhubVN4NzI2c0l1b0ZjQ2pidXM1YnlSNDZfZGl5a1JLdS13V3BTeXdRUEVYOTllY2YtUk1nRXVtMzI3RHdUZmpVclFrSGYyaEw2M0JoOFBTWnBGM3AzcWN6cy05MXR4LXI5N2xTWUNTZk40MHFOYkM5QzVicWpxQjAwNGNkQlUtbTA5R0lBUDEwaEt4UUtxRlhLQzJTSG5kZVFHWHNlQ21CdkVyWEQwNWdB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMkJaOG1LR0kwNzlyTkhubVN4NzI2c0l1b0ZjQ2pidXM1YnlSNDZfZGl5a1JLdS13V3BTeXdRUEVYOTllY2YtUk1nRXVtMzI3RHdUZmpVclFrSGYyaEw2M0JoOFBTWnBGM3AzcWN6cy05MXR4LXI5N2xTWUNTZk40MHFOYkM5QzVicWpxQjAwNGNkQlUtbTA5R0lBUDEwaEt4UUtxRlhLQzJTSG5kZVFHWHNlQ21CdkVyWEQwNWdB?oc=5", "title": "L'action Fermentalg en hausse de 6 % avant ses r\u00e9sultats annuels jeudi", "content_text": "L'action Fermentalg en hausse de 6 % avant ses r\u00e9sultats annuels jeudi", "date_published": "2026-03-30T07:00:00+00:00", "authors": [{"name": "Id\u00e9al Investisseur"}], "tags": ["Market update", "ALGAE"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALGAE", "name": "FERMENTALG", "sentiment_url": "https://sharemaestro.com/sentiment/52542339-8230-437e-9166-056d8826d7fb/"}]}}, {"id": "source:a4af9396256ef8997adc4048ac6e2732ed4d4850c677e0251f338b351ba7fb5f", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ1hsVEtTTGNJTjRGX1EwMmh5V1BuSnV4Wmp3X3JyaV80UGRqYzFpVXpSLXVkNVdKOUF0dVU3VHFEa25keE9wSEUtREFocVJET3pDQ29welU3WGJiWW9fSzJ3Qjl1c0dhU2RiMUwyc3R0Q0gyRVN3eVdKcjl2a1M3VkR2NUpWclRvSG8tRm54Nllfd1lQSWRRcHlkanpQRDdlVWhfbi1WcTBKODZvWDZzWGdnQVNyODhB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ1hsVEtTTGNJTjRGX1EwMmh5V1BuSnV4Wmp3X3JyaV80UGRqYzFpVXpSLXVkNVdKOUF0dVU3VHFEa25keE9wSEUtREFocVJET3pDQ29welU3WGJiWW9fSzJ3Qjl1c0dhU2RiMUwyc3R0Q0gyRVN3eVdKcjl2a1M3VkR2NUpWclRvSG8tRm54Nllfd1lQSWRRcHlkanpQRDdlVWhfbi1WcTBKODZvWDZzWGdnQVNyODhB?oc=5", "title": "MaaT Pharma : r\u00e9sultats cl\u00e9s de Phase 3 d\u00e9voil\u00e9s au congr\u00e8s EBMT 2026", "content_text": "MaaT Pharma : r\u00e9sultats cl\u00e9s de Phase 3 d\u00e9voil\u00e9s au congr\u00e8s EBMT 2026", "date_published": "2026-03-09T07:00:00+00:00", "authors": [{"name": "Id\u00e9al Investisseur"}], "tags": ["Market update", "MAAT"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MAAT", "name": "MaaT Pharma SA", "sentiment_url": "https://sharemaestro.com/sentiment/a1d91df7-9f62-4133-981f-1cdf40d206fa/"}]}}, {"id": "source:0dfe2a1cf5db58a5c3175c0dc1cdf3625ab183977b766ff7550ad3f5c7825a01", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPa0hZc29LaXJPa0NfR1pkM1UyYW9oMmF0c3owSkNIckYtMmZqNjM0a3k5dDJ2VDQtZEJVVk83RDAxaE5LWkdZZU1henlCWGZjN3oxRVZhYkg5anRqdV9PcHE0ZnVMc25KOVNHbjh3TmpmLUxHUGp5VmZBeVZFVjFWZmg4dEJhTktVQnh6T3ZpaXJyUktEWjVWOC0xTHplSzl2YjdHUkk0eUNULTRueWJybFZMVW5WeTRwODAtRUZVQ1F3eC1mT2NjeTV0OGtxSmY1NkpqSFpNajNIc3RE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPa0hZc29LaXJPa0NfR1pkM1UyYW9oMmF0c3owSkNIckYtMmZqNjM0a3k5dDJ2VDQtZEJVVk83RDAxaE5LWkdZZU1henlCWGZjN3oxRVZhYkg5anRqdV9PcHE0ZnVMc25KOVNHbjh3TmpmLUxHUGp5VmZBeVZFVjFWZmg4dEJhTktVQnh6T3ZpaXJyUktEWjVWOC0xTHplSzl2YjdHUkk0eUNULTRueWJybFZMVW5WeTRwODAtRUZVQ1F3eC1mT2NjeTV0OGtxSmY1NkpqSFpNajNIc3RE?oc=5", "title": "Action Valneva : le titre touche sa r\u00e9sistance apr\u00e8s la publication du chiffre d'affaires 2025", "content_text": "Action Valneva : le titre touche sa r\u00e9sistance apr\u00e8s la publication du chiffre d'affaires 2025", "date_published": "2026-02-20T08:00:00+00:00", "authors": [{"name": "Id\u00e9al Investisseur"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:5c4ed7ebf3edd736e39ee72363d6b63f6ace63775de4d44d470c55720440493a", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxNSE1jLURHbWFzT1RrRGMzYmZCZEdpa2s0OHh1SnJPY1JZYUxnQU5WMjFXaWJvLTctMm1tS25yellxU0JWS2JiVzdDRE1EYW9MVUlpNHVMMk1lem9vVWpkS01Pbk5wNTVhQ1RpWWVjLUZWeHRaa3AtblVjeTZyQkdNNTRkaUUzakc1WG4xTDBheGVYbzcwZ25zSE1wU3YxZERoUzRSRURyWjNhZ2dVVEI0WVNEdGkxemJ3TWpOaVlxb2pweXFtZnBwczMweEF0VnltUjhlSXR1clYwUEMwU2hwOU5vekpHY0tqa3Z1ZXpPbzZGek5YdWZpOEdDSVd3VVliWlRtWTZ2cFlJUDZLLTlFU0xpTHFjUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxNSE1jLURHbWFzT1RrRGMzYmZCZEdpa2s0OHh1SnJPY1JZYUxnQU5WMjFXaWJvLTctMm1tS25yellxU0JWS2JiVzdDRE1EYW9MVUlpNHVMMk1lem9vVWpkS01Pbk5wNTVhQ1RpWWVjLUZWeHRaa3AtblVjeTZyQkdNNTRkaUUzakc1WG4xTDBheGVYbzcwZ25zSE1wU3YxZERoUzRSRURyWjNhZ2dVVEI0WVNEdGkxemJ3TWpOaVlxb2pweXFtZnBwczMweEF0VnltUjhlSXR1clYwUEMwU2hwOU5vekpHY0tqa3Z1ZXpPbzZGek5YdWZpOEdDSVd3VVliWlRtWTZ2cFlJUDZLLTlFU0xpTHFjUQ?oc=5", "title": "Valneva : De nouveaux r\u00e9sultats cliniques positifs sur son vaccin contre la maladie de Lyme portent Valneva en Bourse", "content_text": "Valneva : De nouveaux r\u00e9sultats cliniques positifs sur son vaccin contre la maladie de Lyme portent Valneva en Bourse", "date_published": "2025-11-26T08:00:00+00:00", "authors": [{"name": "BFM Bourse"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:714fad8ce3f172d75c4a9183404546c7f7023ae44e863ecda2a5f9976f240874", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOVkJZX3N0Y05NNHFGYm5idC1RR1dUWU1ROFpjZUVvUWEyX0JJZHJyX3NrREl3TC1leEpxYm5rQmpqT1hJdlZoTVZPeUlXUWRuLWxwR3hyZ0g1TVRFcU5ZOXNkT1pFdXh1aEVzWFN0Y2k0Vkt2ZDRnYkdKLTliTGNQSm16RmFDWUtsUTUySTJSNGFwYkVVSTVzZVdRd25BSkFqMmNKeDhvV2pJUHY1Vmc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOVkJZX3N0Y05NNHFGYm5idC1RR1dUWU1ROFpjZUVvUWEyX0JJZHJyX3NrREl3TC1leEpxYm5rQmpqT1hJdlZoTVZPeUlXUWRuLWxwR3hyZ0g1TVRFcU5ZOXNkT1pFdXh1aEVzWFN0Y2k0Vkt2ZDRnYkdKLTliTGNQSm16RmFDWUtsUTUySTJSNGFwYkVVSTVzZVdRd25BSkFqMmNKeDhvV2pJUHY1Vmc?oc=5", "title": "Valneva reporte sa dette \u00e0 2030 et ajuste ses pr\u00e9visions \u00e0 la baisse", "content_text": "Valneva reporte sa dette \u00e0 2030 et ajuste ses pr\u00e9visions \u00e0 la baisse", "date_published": "2025-10-06T07:00:00+00:00", "authors": [{"name": "ABC Bourse"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:dad673fed67c625b436ccffd237ab9a751c2ffd8d0f7cde8e397e681e1552fd8", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFBabkx6WmIxTVFxLWtMMXpvYXo1RURyTXIza3hoYWZuekVuOUZ6UEc1VUV4OEdOQTZRNlEtc05SNXNNNXYzMTNxOFk5TlA4U3FwUHc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFBabkx6WmIxTVFxLWtMMXpvYXo1RURyTXIza3hoYWZuekVuOUZ6UEc1VUV4OEdOQTZRNlEtc05SNXNNNXYzMTNxOFk5TlA4U3FwUHc?oc=5", "title": "Le prix de l'action Abivax SA (ABVX.PA) : Actualit\u00e9s et pr\u00e9visions des analystes", "content_text": "Le prix de l'action Abivax SA (ABVX.PA) : Actualit\u00e9s et pr\u00e9visions des analystes", "date_published": "2024-12-09T07:19:50+00:00", "authors": [{"name": "eToro"}], "tags": ["Market update", "ABVX"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABVX", "name": "ABIVAX Soci\u00e9t\u00e9 Anonyme", "sentiment_url": "https://sharemaestro.com/sentiment/31eb5de8-5e84-4e38-ba2e-0b160353627c/"}]}}, {"id": "source:14a0e1c87d8c1576130043e9a5385304f12e8f8fa705c35555faf8934db7cc09", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5uQ3FMa3lUT0ZybVIzQWV5NEhwdGVGTTk0VGY4QjJlRUF4dVdzZF9tLXpCNm5obXd0S29XdU5hYlkyc0diNUNBbm83eFU3MzAta3lfSXBYTHhZS3pZSnF2NWpuNGc4VmZ4d2ZGaW9HLWtabXlv?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5uQ3FMa3lUT0ZybVIzQWV5NEhwdGVGTTk0VGY4QjJlRUF4dVdzZF9tLXpCNm5obXd0S29XdU5hYlkyc0diNUNBbm83eFU3MzAta3lfSXBYTHhZS3pZSnF2NWpuNGc4VmZ4d2ZGaW9HLWtabXlv?oc=5", "title": "Valneva SE: Pr\u00e9visions et Estimations des Analystes | VLA", "content_text": "Valneva SE: Pr\u00e9visions et Estimations des Analystes | VLA", "date_published": "2024-07-26T00:01:01+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:219de5317b9c19d4f72dd69498b50c88a29705890e55bf3daf80e57405af9e06", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPN3lZTUt2VXFKUkQzcllqdGVhUFl2SmZWVXJmWkpORzY5ZWlNd1V3dkxFTEk1T3hFNHNNeEsxYW4zb244cDVSUE1EaURURGI1OXFSRzFrcXVRVWhsQ0U3T0d1bHUwMEQ1R1FGRHp1Q1JoVjBpRDRqdTkxcmxDMG9GWmktdXdoVkpP?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPN3lZTUt2VXFKUkQzcllqdGVhUFl2SmZWVXJmWkpORzY5ZWlNd1V3dkxFTEk1T3hFNHNNeEsxYW4zb244cDVSUE1EaURURGI1OXFSRzFrcXVRVWhsQ0U3T0d1bHUwMEQ1R1FGRHp1Q1JoVjBpRDRqdTkxcmxDMG9GWmktdXdoVkpP?oc=5", "title": "GenSight Biologics S.A.: Pr\u00e9visions et Estimations des Analystes | SIGHT", "content_text": "GenSight Biologics S.A.: Pr\u00e9visions et Estimations des Analystes | SIGHT", "date_published": "2024-07-23T12:27:04+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "SIGHT"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SIGHT", "name": "GenSight Biologics S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/af88c2ee-4e37-4fa8-a649-1cdb4cc7dd56/"}]}}, {"id": "source:542710a3f3805911e346b4210dfb96e5088b1c8ef8c55030c581632f35b7cf2a", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBrUHAwSk1nemxaVzVKaHFkR1B3YTRia05VOE5BYW55aE9ja1NoMVRPWDZIYVZ3c3RULU1aWVR1OEs1S3pweWVmZ3hOakpJeHZNZmhsOW9XQUhNVi1TZ0tiS0VhUmdEcE9idHJQcWdTSjMzaTBZVGw2ZQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBrUHAwSk1nemxaVzVKaHFkR1B3YTRia05VOE5BYW55aE9ja1NoMVRPWDZIYVZ3c3RULU1aWVR1OEs1S3pweWVmZ3hOakpJeHZNZmhsOW9XQUhNVi1TZ0tiS0VhUmdEcE9idHJQcWdTSjMzaTBZVGw2ZQ?oc=5", "title": "Fermentalg: Pr\u00e9visions et Estimations des Analystes | ALGAE", "content_text": "Fermentalg: Pr\u00e9visions et Estimations des Analystes | ALGAE", "date_published": "2024-07-23T09:15:43+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "ALGAE"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALGAE", "name": "FERMENTALG", "sentiment_url": "https://sharemaestro.com/sentiment/52542339-8230-437e-9166-056d8826d7fb/"}]}}, {"id": "source:021ddb0844fc06860232ac8b77752cb281fd4a90926c81eb242c0bb0d8a45337", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBUUGJYdkx1Tzc0YWRCZXU1SnA5NnZxekhxczdCOWNFajhZV2R1RVgzQ29pc0ZjSC14TGM3U3ppcnBhVThOVDVjU1hMVlV6cjdyQTRielEzTTNwMk1aRVJReVluU3NtV1BvVkFpWXVfOXNGaTh6YVNFZDFKQ0M?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBUUGJYdkx1Tzc0YWRCZXU1SnA5NnZxekhxczdCOWNFajhZV2R1RVgzQ29pc0ZjSC14TGM3U3ppcnBhVThOVDVjU1hMVlV6cjdyQTRielEzTTNwMk1aRVJReVluU3NtV1BvVkFpWXVfOXNGaTh6YVNFZDFKQ0M?oc=5", "title": "MedinCell S.A.: Pr\u00e9visions et Estimations des Analystes | MEDCL", "content_text": "MedinCell S.A.: Pr\u00e9visions et Estimations des Analystes | MEDCL", "date_published": "2024-07-23T08:04:40+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "MEDCL"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MEDCL", "name": "MedinCell S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c1a6a004-ed02-43d9-a6ea-21f7d30551c3/"}]}}, {"id": "source:54cd623c2820f3135634b5ddefc72ae7cc8e5eb0d0b97e2f32ab720ac5d4cd7a", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE5UOFMzY05TeS1UNk1KMThySXd4dXhzNU9CSER0ZVE2Y0dheEZuVEgyY1d0QTU0NGI3TlprQlowTDZQNDZUWG1CS3VJeURRbkdWbXpUd3FDWEowdXNIQjFV?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE5UOFMzY05TeS1UNk1KMThySXd4dXhzNU9CSER0ZVE2Y0dheEZuVEgyY1d0QTU0NGI3TlprQlowTDZQNDZUWG1CS3VJeURRbkdWbXpUd3FDWEowdXNIQjFV?oc=5", "title": "Action Medincell SA | Cours | Dividende | Actus (A2N6VA, FR0004065605)", "content_text": "Action Medincell SA | Cours | Dividende | Actus (A2N6VA, FR0004065605)", "date_published": "2023-08-11T07:00:00+00:00", "authors": [{"name": "extraETF"}], "tags": ["Market update", "MEDCL"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MEDCL", "name": "MedinCell S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c1a6a004-ed02-43d9-a6ea-21f7d30551c3/"}]}}, {"id": "source:e4cc009b4de2fd88d92422de942b36657d632d77bc0a490b5ba067e7c2458b3c", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZXAzeXpsTV9uWjNLcEV2SlZlT19LZHNCX0ktRW0tMVRXTlVnYTFfdjgwWDRMNnlBVFBBT20wQzRoQjZ5eXcxUTFnQVlVR0hYdHZfdVFUZWc0MjFaSmE5WFZJOE1XLVoxYUxGZDBiTWpmdXpWWnhwZ1FLLWQ3ZjRLdFljRkRfLVBPbUNRUmduU3l5ZWNaNkdiVEFtQk54U0VPY2Fr?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZXAzeXpsTV9uWjNLcEV2SlZlT19LZHNCX0ktRW0tMVRXTlVnYTFfdjgwWDRMNnlBVFBBT20wQzRoQjZ5eXcxUTFnQVlVR0hYdHZfdVFUZWc0MjFaSmE5WFZJOE1XLVoxYUxGZDBiTWpmdXpWWnhwZ1FLLWQ3ZjRLdFljRkRfLVBPbUNRUmduU3l5ZWNaNkdiVEFtQk54U0VPY2Fr?oc=5", "title": "MedinCell S.A. (MEDCL) - Cours Action | FR0004065605 - Cotation EURONEXT PARIS", "content_text": "MedinCell S.A. (MEDCL) - Cours Action | FR0004065605 - Cotation EURONEXT PARIS", "date_published": "2021-06-04T13:15:33+00:00", "authors": [{"name": "boursedirect.fr"}], "tags": ["Market update", "MEDCL"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MEDCL", "name": "MedinCell S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c1a6a004-ed02-43d9-a6ea-21f7d30551c3/"}]}}, {"id": "source:53a9e45bd2c0f52951969c084040ab3542c89b26f1cf1236c8cf41d1f5cd990d", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTFBBLTMyVmVEWjNsek0wQjExSUltNWl5cmFwQ0UtT3IzZmU0dnladDFqa3BuTmVna240X093VUctZWdMQk1ybGRPVzFfRGxNV1ZwMFpiTzF0NV9FVWkzMFRjYllGTEM0cE9NXzZWakJIM3BpeDJnNnRmSk93?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiekFVX3lxTFBBLTMyVmVEWjNsek0wQjExSUltNWl5cmFwQ0UtT3IzZmU0dnladDFqa3BuTmVna240X093VUctZWdMQk1ybGRPVzFfRGxNV1ZwMFpiTzF0NV9FVWkzMFRjYllGTEM0cE9NXzZWakJIM3BpeDJnNnRmSk93?oc=5", "title": "Cellectis S.A.: Objectif de Cours et Consensus des Analystes | ALCLS | FR0010425595", "content_text": "Cellectis S.A.: Objectif de Cours et Consensus des Analystes | ALCLS | FR0010425595", "date_published": "2021-03-28T22:52:41+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "ALCLS"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALCLS", "name": "Cellectis S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/094ba8d4-1a5b-4ff5-a789-630e49274513/"}]}}, {"id": "source:d5e013fa12c073e72630ce587c91309ac90f0c4a0a82d2204130cbc86cb6d942", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1URDNSdzlTLW02dGdzY19wdU1yYXVtT1Axb2F2SWxjcHJyQ01SWWpYZEt5U2hnejc5TUl0ZnFQcTBFMzhaX215YmVURG44REVHZ3c4RmhLUk5Pem1mQjNPUno2d2NNSDRLZFB3dWhZNnp0QWdlVjdBNTJR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1URDNSdzlTLW02dGdzY19wdU1yYXVtT1Axb2F2SWxjcHJyQ01SWWpYZEt5U2hnejc5TUl0ZnFQcTBFMzhaX215YmVURG44REVHZ3c4RmhLUk5Pem1mQjNPUno2d2NNSDRLZFB3dWhZNnp0QWdlVjdBNTJR?oc=5", "title": "Cellectis S.A.: Analyse Fondamentale et Notations Financi\u00e8res | ALCLS | FR0010425595", "content_text": "Cellectis S.A.: Analyse Fondamentale et Notations Financi\u00e8res | ALCLS | FR0010425595", "date_published": "2021-03-27T07:27:51+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "ALCLS"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALCLS", "name": "Cellectis S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/094ba8d4-1a5b-4ff5-a789-630e49274513/"}]}}, {"id": "source:f9faac7549cf70be49326377035bfe7ce31abfdb3e9b0860667a9de134f84d12", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9QN1Y1T1Jyb3FQZEJKdUgybjRlNXBXODYzNmlSN0Z6WHB3TnpkRFdDRDQtdk85YUl3T2JPZDFSbm1sMEM5bWx2WTlsYzVhWnc4OTMtZWVGXzZxOVk1cWR6dUxrenNWX1lGaWM5dVBDVE1NWFBlLXpROTE5TjdFUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9QN1Y1T1Jyb3FQZEJKdUgybjRlNXBXODYzNmlSN0Z6WHB3TnpkRFdDRDQtdk85YUl3T2JPZDFSbm1sMEM5bWx2WTlsYzVhWnc4OTMtZWVGXzZxOVk1cWR6dUxrenNWX1lGaWM5dVBDVE1NWFBlLXpROTE5TjdFUQ?oc=5", "title": "MedinCell S.A.: Objectif de Cours et Consensus des Analystes | MEDCL | FR0004065605", "content_text": "MedinCell S.A.: Objectif de Cours et Consensus des Analystes | MEDCL | FR0004065605", "date_published": "2020-10-22T12:40:46+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "MEDCL"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MEDCL", "name": "MedinCell S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c1a6a004-ed02-43d9-a6ea-21f7d30551c3/"}]}}, {"id": "source:8deec1f4a4198d75d6f0b7c645bbaf5f6827486ce1ff0a5ac457e49b3459435e", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBEdDdtZmRsMUNxM3FoWVpNd0VWS1FGeFdfcnliSEFCempicFlLN0hoa2lVTGViVnE3ekxLVDJmaE1rbEdYbGJlZVlPendXemdYMW50cmhPZUNxa0tPSTVzLXNDY3haclB3TFpfQkxpbzRsdS1rUWpBSE5jakk5QQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBEdDdtZmRsMUNxM3FoWVpNd0VWS1FGeFdfcnliSEFCempicFlLN0hoa2lVTGViVnE3ekxLVDJmaE1rbEdYbGJlZVlPendXemdYMW50cmhPZUNxa0tPSTVzLXNDY3haclB3TFpfQkxpbzRsdS1rUWpBSE5jakk5QQ?oc=5", "title": "MedinCell S.A.: Analyse Fondamentale et Notations Financi\u00e8res | MEDCL | FR0004065605", "content_text": "MedinCell S.A.: Analyse Fondamentale et Notations Financi\u00e8res | MEDCL | FR0004065605", "date_published": "2020-10-22T12:40:45+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "MEDCL"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MEDCL", "name": "MedinCell S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c1a6a004-ed02-43d9-a6ea-21f7d30551c3/"}]}}, {"id": "source:21b486478ab0fa9d2fb9b2a3c2d95760c94556a935e0c8846d25315e7dcc7c5d", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPQjhmRUNYdlI4NXNYeld4YzhmQjBPUUdDUDhCbTVraGRvUFNqVWRJYkNHVFBpUUVRNnhHb2t1MGdfQS1yd1ZTa3hseUc2MVAyb2tsaklLOUc2amlnRldXNTgxR3NBMW9MMGI2X0xUcDdvb21kVTVIeFVUazdZWXRsQ25vc3pnNjN5bXc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPQjhmRUNYdlI4NXNYeld4YzhmQjBPUUdDUDhCbTVraGRvUFNqVWRJYkNHVFBpUUVRNnhHb2t1MGdfQS1yd1ZTa3hseUc2MVAyb2tsaklLOUc2amlnRldXNTgxR3NBMW9MMGI2X0xUcDdvb21kVTVIeFVUazdZWXRsQ25vc3pnNjN5bXc?oc=5", "title": "GenSight Biologics S.A.: Objectif de Cours et Consensus des Analystes | SIGHT | FR0013183985", "content_text": "GenSight Biologics S.A.: Objectif de Cours et Consensus des Analystes | SIGHT | FR0013183985", "date_published": "2020-08-24T13:55:32+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "SIGHT"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SIGHT", "name": "GenSight Biologics S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/af88c2ee-4e37-4fa8-a649-1cdb4cc7dd56/"}]}}, {"id": "source:30b10ac9e5068d048872546e394d8671504b93bbf3aa0d56047d76032e8c6134", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE5wdmlaSVdTVWVGY2xiVjhVYk9PbENERUY2TllpdEU5WngyUk85S1hwbnVaUGlYUjRCdm1ldUZNeDBVOEVQbFdqZE95cXVzektCZ0ZZS0pTX052aF82ODUtN2VmaHNzaWVGVTZfYV80aHdVb0Z6VGc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE5wdmlaSVdTVWVGY2xiVjhVYk9PbENERUY2TllpdEU5WngyUk85S1hwbnVaUGlYUjRCdm1ldUZNeDBVOEVQbFdqZE95cXVzektCZ0ZZS0pTX052aF82ODUtN2VmaHNzaWVGVTZfYV80aHdVb0Z6VGc?oc=5", "title": "Valneva SE: Analyse Fondamentale et Notations Financi\u00e8res | VLA | FR0004056851", "content_text": "Valneva SE: Analyse Fondamentale et Notations Financi\u00e8res | VLA | FR0004056851", "date_published": "2020-08-23T18:56:35+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "VLA"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VLA", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/29755642-e05f-4073-89cd-1a3af2a51d87/"}]}}, {"id": "source:d8e445e8bc159618f1b3a9a8f1bc63ba1daaaf6e33f41a2bb8c580002bbaa65a", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9QSnphd1N5YzZYWUdIOEdhRmcwYzV6OHlnV0VlMFFYeVpPSkh1SHQ0S0dwTmpQdVU2QVNJTkdMR0J5SG02a2RjUE9LZ2dUUUJKTURVRk44eW1kN1FnaVZla0RYNWdSLWRldHNBTTFNSHVRc1FLRFNiNXFn?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9QSnphd1N5YzZYWUdIOEdhRmcwYzV6OHlnV0VlMFFYeVpPSkh1SHQ0S0dwTmpQdVU2QVNJTkdMR0J5SG02a2RjUE9LZ2dUUUJKTURVRk44eW1kN1FnaVZla0RYNWdSLWRldHNBTTFNSHVRc1FLRFNiNXFn?oc=5", "title": "Innate Pharma: Analyse Fondamentale et Notations Financi\u00e8res | IPH | FR0010331421", "content_text": "Innate Pharma: Analyse Fondamentale et Notations Financi\u00e8res | IPH | FR0010331421", "date_published": "2020-08-23T15:36:00+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "IPH"], "_sharemaestro": {"country": "France", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IPH", "name": "Innate Pharma S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6c317cc7-90f7-4370-b7d0-abc75a3227ae/"}]}}]}